Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin

Theodora Hatziioannou, Edwige Delahaye, Fransisco Martin, Stephen J Russell, François Loïc Cosset

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We have previously shown that retroviral vector particles derived from Moloney murine leukemia virus (MoMuLV) can efficiently incorporate influenza hemagglutinin (HA) glycoproteins from fowl plague virus (FPV), thus conferring a broad tropism to the vectors. To modify its host range, we have engineered the FPV HA to display four different polypeptides on its N terminus: the epidermal growth factor, an anti-human MHC class I molecules scFv (single-chain antibody), an anti-melanoma antigen scFv, and an IgG Fc- binding polypeptide. All recombinant HA glycoproteins were correctly expressed and processed, and efficiently incorporated into Mo-MuLV retroviral particles, indicating that amino-terminal insertion of large polypeptides did not alter the conformation of HA chimeras. Virions carrying the different chimeras bound specifically to cells expressing the targeted cell surface molecules of each ligand. In addition, all virion types were infectious but exhibited various degrees of specificity regarding the use of the targeted cell surface molecule versus the wild-type FPV HA receptor for cell entry and infection. For some ligands tested, infectivity was significantly increased on cells that express the targeted receptor, compared with cells that express only the wild-type HA receptor. Furthermore, some polypeptides could abolish infectivity via the wild-type FPV HA receptor. Our data therefore indicate that it is possible to engineer the HA envelope glycoprotein by fusing ligands to its amino-terminal end without affecting its fusion activity.

Original languageEnglish (US)
Pages (from-to)1533-1544
Number of pages12
JournalHuman Gene Therapy
Volume10
Issue number9
DOIs
StatePublished - Jun 10 1999

Fingerprint

Hemagglutinins
Human Influenza
Influenza A virus
Virus Receptors
Glycoproteins
Peptides
Ligands
Virion
Melanoma-Specific Antigens
Moloney murine leukemia virus
Single-Chain Antibodies
Tropism
Host Specificity
Epidermal Growth Factor
Immunoglobulin G
Infection

ASJC Scopus subject areas

  • Genetics

Cite this

Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. / Hatziioannou, Theodora; Delahaye, Edwige; Martin, Fransisco; Russell, Stephen J; Cosset, François Loïc.

In: Human Gene Therapy, Vol. 10, No. 9, 10.06.1999, p. 1533-1544.

Research output: Contribution to journalArticle

Hatziioannou, Theodora ; Delahaye, Edwige ; Martin, Fransisco ; Russell, Stephen J ; Cosset, François Loïc. / Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. In: Human Gene Therapy. 1999 ; Vol. 10, No. 9. pp. 1533-1544.
@article{463d2652d51947b6879d83d905a41531,
title = "Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin",
abstract = "We have previously shown that retroviral vector particles derived from Moloney murine leukemia virus (MoMuLV) can efficiently incorporate influenza hemagglutinin (HA) glycoproteins from fowl plague virus (FPV), thus conferring a broad tropism to the vectors. To modify its host range, we have engineered the FPV HA to display four different polypeptides on its N terminus: the epidermal growth factor, an anti-human MHC class I molecules scFv (single-chain antibody), an anti-melanoma antigen scFv, and an IgG Fc- binding polypeptide. All recombinant HA glycoproteins were correctly expressed and processed, and efficiently incorporated into Mo-MuLV retroviral particles, indicating that amino-terminal insertion of large polypeptides did not alter the conformation of HA chimeras. Virions carrying the different chimeras bound specifically to cells expressing the targeted cell surface molecules of each ligand. In addition, all virion types were infectious but exhibited various degrees of specificity regarding the use of the targeted cell surface molecule versus the wild-type FPV HA receptor for cell entry and infection. For some ligands tested, infectivity was significantly increased on cells that express the targeted receptor, compared with cells that express only the wild-type HA receptor. Furthermore, some polypeptides could abolish infectivity via the wild-type FPV HA receptor. Our data therefore indicate that it is possible to engineer the HA envelope glycoprotein by fusing ligands to its amino-terminal end without affecting its fusion activity.",
author = "Theodora Hatziioannou and Edwige Delahaye and Fransisco Martin and Russell, {Stephen J} and Cosset, {Fran{\cc}ois Lo{\"i}c}",
year = "1999",
month = "6",
day = "10",
doi = "10.1089/10430349950017860",
language = "English (US)",
volume = "10",
pages = "1533--1544",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin

AU - Hatziioannou, Theodora

AU - Delahaye, Edwige

AU - Martin, Fransisco

AU - Russell, Stephen J

AU - Cosset, François Loïc

PY - 1999/6/10

Y1 - 1999/6/10

N2 - We have previously shown that retroviral vector particles derived from Moloney murine leukemia virus (MoMuLV) can efficiently incorporate influenza hemagglutinin (HA) glycoproteins from fowl plague virus (FPV), thus conferring a broad tropism to the vectors. To modify its host range, we have engineered the FPV HA to display four different polypeptides on its N terminus: the epidermal growth factor, an anti-human MHC class I molecules scFv (single-chain antibody), an anti-melanoma antigen scFv, and an IgG Fc- binding polypeptide. All recombinant HA glycoproteins were correctly expressed and processed, and efficiently incorporated into Mo-MuLV retroviral particles, indicating that amino-terminal insertion of large polypeptides did not alter the conformation of HA chimeras. Virions carrying the different chimeras bound specifically to cells expressing the targeted cell surface molecules of each ligand. In addition, all virion types were infectious but exhibited various degrees of specificity regarding the use of the targeted cell surface molecule versus the wild-type FPV HA receptor for cell entry and infection. For some ligands tested, infectivity was significantly increased on cells that express the targeted receptor, compared with cells that express only the wild-type HA receptor. Furthermore, some polypeptides could abolish infectivity via the wild-type FPV HA receptor. Our data therefore indicate that it is possible to engineer the HA envelope glycoprotein by fusing ligands to its amino-terminal end without affecting its fusion activity.

AB - We have previously shown that retroviral vector particles derived from Moloney murine leukemia virus (MoMuLV) can efficiently incorporate influenza hemagglutinin (HA) glycoproteins from fowl plague virus (FPV), thus conferring a broad tropism to the vectors. To modify its host range, we have engineered the FPV HA to display four different polypeptides on its N terminus: the epidermal growth factor, an anti-human MHC class I molecules scFv (single-chain antibody), an anti-melanoma antigen scFv, and an IgG Fc- binding polypeptide. All recombinant HA glycoproteins were correctly expressed and processed, and efficiently incorporated into Mo-MuLV retroviral particles, indicating that amino-terminal insertion of large polypeptides did not alter the conformation of HA chimeras. Virions carrying the different chimeras bound specifically to cells expressing the targeted cell surface molecules of each ligand. In addition, all virion types were infectious but exhibited various degrees of specificity regarding the use of the targeted cell surface molecule versus the wild-type FPV HA receptor for cell entry and infection. For some ligands tested, infectivity was significantly increased on cells that express the targeted receptor, compared with cells that express only the wild-type HA receptor. Furthermore, some polypeptides could abolish infectivity via the wild-type FPV HA receptor. Our data therefore indicate that it is possible to engineer the HA envelope glycoprotein by fusing ligands to its amino-terminal end without affecting its fusion activity.

UR - http://www.scopus.com/inward/record.url?scp=0033542387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033542387&partnerID=8YFLogxK

U2 - 10.1089/10430349950017860

DO - 10.1089/10430349950017860

M3 - Article

C2 - 10395378

AN - SCOPUS:0033542387

VL - 10

SP - 1533

EP - 1544

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 9

ER -